📰 Full Story
Ionis Pharmaceuticals Executive Vice President C. Frank Bennett sold 85,089 shares of company stock on Feb. 2, 2026, at an average price of $82.93, generating approximately $7.06 million in proceeds, according to an SEC filing.
After the transaction Bennett directly holds 80,293 shares, a reduction of roughly 51.45% in his reported position.
The sale follows additional disposals by Bennett in January (5,885 and 8,977-share trades) and, according to GuruFocus, brings his total sales over the past year to about 154,860 shares.
At the time of the trade Ionis (NASDAQ: IONS) was trading near its 12‑month high (~$86.15) and had a market capitalisation of roughly $13.77 billion.
Analysts maintain a generally positive consensus — MarketBeat cites a “moderate buy” average rating and a consensus target near $86.45 — while institutional investors hold a large portion of the stock (reported at about 93.9%). The company, a U.S.-based developer of RNA-targeted therapeutics, disclosed the trade in a standard SEC filing.























💬 Commentary